{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:46:31Z","timestamp":1792669591765,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T00:00:00Z","timestamp":1340668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1038\/nrgastro.2012.119","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T12:49:30Z","timestamp":1340714970000},"page":"435-444","source":"Crossref","is-referenced-by-count":173,"title":["New biomarkers and targets in pancreatic cancer and their application to treatment"],"prefix":"10.1038","volume":"9","author":[{"given":"Eithne","family":"Costello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Greenhalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Neoptolemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,26]]},"reference":[{"key":"BFnrgastro2012119_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765\u2013781 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2012119_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10\u201329 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrgastro2012119_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent, A., Herman, J., Schulick, R., Hruban, R. H. & Goggins, M. Pancreatic cancer. Lancet 378, 607\u2013620 (2011).","journal-title":"Lancet"},{"key":"BFnrgastro2012119_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/bjs.7581","volume":"98","author":"VE Lemmens","year":"2011","unstructured":"Lemmens, V. E. et al. Improving outcome for patients with pancreatic cancer through centralization. Br. J. Surg. 98, 1455\u20131462 (2011).","journal-title":"Br. J. Surg."},{"key":"BFnrgastro2012119_CR5","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/gut.2006.113068","volume":"56","author":"P Ghaneh","year":"2007","unstructured":"Ghaneh, P., Costello, E. & Neoptolemos, J. P. Biology and management of pancreatic cancer. Gut 56, 1134\u20131152 (2007).","journal-title":"Gut"},{"key":"BFnrgastro2012119_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200\u20131210 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2012119_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.bjc.6604838","volume":"100","author":"JP Neoptolemos","year":"2009","unstructured":"Neoptolemos, J. P. et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br. J. Cancer 100, 246\u2013250 (2009).","journal-title":"Br. J. Cancer"},{"key":"BFnrgastro2012119_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073\u20131081 (2010).","journal-title":"JAMA"},{"key":"BFnrgastro2012119_CR9","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513\u20135518 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrclinonc.2009.236","volume":"7","author":"A Stathis","year":"2010","unstructured":"Stathis, A. & Moore, M. J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 7, 163\u2013172 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrgastro2012119_CR11","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801\u20131806 (2008).","journal-title":"Science"},{"key":"BFnrgastro2012119_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature09460","volume":"467","author":"PJ Campbell","year":"2010","unstructured":"Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109\u20131113 (2010).","journal-title":"Nature"},{"key":"BFnrgastro2012119_CR13","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114\u20131117 (2010).","journal-title":"Nature"},{"key":"BFnrgastro2012119_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","volume":"148","author":"H Haeno","year":"2012","unstructured":"Haeno, H. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148, 362\u2013375 (2012).","journal-title":"Cell"},{"key":"BFnrgastro2012119_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2011.12.021","volume":"148","author":"DA Tuveson","year":"2012","unstructured":"Tuveson, D. A. & Neoptolemos, J. P. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148, 21\u201323 (2012).","journal-title":"Cell"},{"key":"BFnrgastro2012119_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349\u2013361 (2012).","journal-title":"Cell"},{"key":"BFnrgastro2012119_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500\u2013503 (2011).","journal-title":"Nat. Med."},{"key":"BFnrgastro2012119_CR18","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403\u20132413 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR19","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960\u20131966 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2012.01.014","volume":"148","author":"JE Dancey","year":"2012","unstructured":"Dancey, J. E., Bedard, P. L., Onetto, N. & Hudson, T. J. The genetic basis for cancer treatment decisions. Cell 148, 409\u2013420 (2012).","journal-title":"Cell"},{"key":"BFnrgastro2012119_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00423-004-0486-7","volume":"389","author":"MJ Tisdale","year":"2004","unstructured":"Tisdale, M. J. Cancer cachexia. Langenbecks Arch. Surg. 389, 299\u2013305 (2004).","journal-title":"Langenbecks Arch. Surg."},{"key":"BFnrgastro2012119_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.lfs.2010.11.011","volume":"88","author":"K Felix","year":"2011","unstructured":"Felix, K. et al. Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci. 88, 218\u2013225 (2011).","journal-title":"Life Sci."},{"key":"BFnrgastro2012119_CR23","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2012119_CR24","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/jnci\/djp335","volume":"101","author":"RM Simon","year":"2009","unstructured":"Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446\u20131452 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrgastro2012119_CR25","doi-asserted-by":"publisher","unstructured":"Erkan, M. et al. The role of stroma in pancreatic cancer\u2014diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. http:\/\/dx.doi\/org\/10.1038\/nrgastro.2012.115 .","DOI":"10.1038\/nrgastro.2012.115"},{"key":"BFnrgastro2012119_CR26","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-08-2080","volume":"15","author":"R Marechal","year":"2009","unstructured":"Marechal, R. et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15, 2913\u20132919 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrgastro2012119_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","volume":"136","author":"JJ Farrell","year":"2009","unstructured":"Farrell, J. J. et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136, 187\u2013195 (2009).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012119_CR28","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","volume":"299","author":"WF Regine","year":"2008","unstructured":"Regine, W. F. et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299, 1019\u20131026 (2008).","journal-title":"JAMA"},{"key":"BFnrgastro2012119_CR29","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","volume":"18","author":"WF Regine","year":"2011","unstructured":"Regine, W. F. et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the, U. S. Intergroup\/RTOG 9704 phase III trial. Ann. Surg. Oncol. 18, 1319\u20131326 (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrgastro2012119_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle, H. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297, 267\u2013277 (2007).","journal-title":"JAMA"},{"key":"BFnrgastro2012119_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/bjs.7556","volume":"98","author":"E Costello","year":"2011","unstructured":"Costello, E. & Neoptolemos, J. Enhancing the translation of cancer biomarkers. Br. J. Surg. 98, 1039\u20131040 (2011).","journal-title":"Br. J. Surg."},{"key":"BFnrgastro2012119_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane, L. M. et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93, 387\u2013391 (2005).","journal-title":"Br. J. Cancer"},{"key":"BFnrgastro2012119_CR33","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-10-0880","volume":"16","author":"SN Khleif","year":"2010","unstructured":"Khleif, S. N., Doroshow, J. H. & Hait, W. N. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin. Cancer Res. 16, 3299\u20133318 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrgastro2012119_CR34","first-page":"11","volume":"22","author":"V Heinemann","year":"1995","unstructured":"Heinemann, V., Schulz, L., Issels, R. D. & Plunkett, W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin. Oncol. 22, 11\u201318 (1995).","journal-title":"Semin. Oncol."},{"key":"BFnrgastro2012119_CR35","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1002\/cncr.25303","volume":"116","author":"R Marechal","year":"2010","unstructured":"Marechal, R. et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116, 5200\u20135206 (2010).","journal-title":"Cancer"},{"key":"BFnrgastro2012119_CR36","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-09-0371","volume":"69","author":"CL Costantino","year":"2009","unstructured":"Costantino, C. L. et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 69, 4567\u20134572 (2009).","journal-title":"Cancer Res."},{"key":"BFnrgastro2012119_CR37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/SLA.0b013e3181f1fd44","volume":"252","author":"NG Richards","year":"2010","unstructured":"Richards, N. G. et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg. 252, 499\u2013505 (2010).","journal-title":"Ann. Surg."},{"key":"BFnrgastro2012119_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2407-12-104","volume":"12","author":"ME Valsecchi","year":"2012","unstructured":"Valsecchi, M. E. et al. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer 12, 104 (2012).","journal-title":"BMC Cancer"},{"key":"BFnrgastro2012119_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejca.2009.10.027","volume":"46","author":"R Hummel","year":"2010","unstructured":"Hummel, R., Hussey, D. J. & Haier, J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur. J. Cancer 46, 298\u2013311 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2012119_CR40","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1586\/era.11.184","volume":"11","author":"AE Frampton","year":"2011","unstructured":"Frampton, A. E. et al. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev. Anticancer Ther. 11, 1837\u20131842 (2011).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"BFnrgastro2012119_CR41","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1158\/0008-5472.CAN-09-4467","volume":"70","author":"E Giovannetti","year":"2010","unstructured":"Giovannetti, E. et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528\u20134538 (2010).","journal-title":"Cancer Res."},{"key":"BFnrgastro2012119_CR42","doi-asserted-by":"publisher","first-page":"e10630","DOI":"10.1371\/journal.pone.0010630","volume":"5","author":"JH Hwang","year":"2010","unstructured":"Hwang, J. H. et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5, e10630 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2012119_CR43","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1158\/1078-0432.CCR-11-0695","volume":"17","author":"M Preis","year":"2011","unstructured":"Preis, M. et al. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 17, 5812\u20135821 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrgastro2012119_CR44","doi-asserted-by":"publisher","first-page":"e34151","DOI":"10.1371\/journal.pone.0034151","volume":"7","author":"AS Bauer","year":"2012","unstructured":"Bauer, A. S. et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS ONE 7, e34151 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2012119_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0002-9610(99)00086-0","volume":"177","author":"F Miyazono","year":"1999","unstructured":"Miyazono, F. et al. Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. Am. J. Surg. 177, 475\u2013479 (1999).","journal-title":"Am. J. Surg."},{"key":"BFnrgastro2012119_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000335479","volume":"82","author":"A de Albuquerque","year":"2012","unstructured":"de Albuquerque, A. et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 82, 3\u201310 (2012).","journal-title":"Oncology"},{"key":"BFnrgastro2012119_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00534-007-1250-5","volume":"15","author":"T Kurihara","year":"2008","unstructured":"Kurihara, T. et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J. Hepatobiliary Pancreat. Surg. 15, 189\u2013195 (2008).","journal-title":"J. Hepatobiliary Pancreat. Surg."},{"key":"BFnrgastro2012119_CR48","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-10-3019","volume":"17","author":"D Olmos","year":"2011","unstructured":"Olmos, D. et al. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin. Cancer Res. 17, 5188\u20135196 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrgastro2012119_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/gut.2010.226092","volume":"60","author":"A Neesse","year":"2010","unstructured":"Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861\u2013868 (2010).","journal-title":"Gut"},{"key":"BFnrgastro2012119_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tig.2008.10.012","volume":"25","author":"K Polyak","year":"2009","unstructured":"Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30\u201338 (2009).","journal-title":"Trends Genet."},{"key":"BFnrgastro2012119_CR51","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904\u20135912 (2008).","journal-title":"Oncogene"},{"key":"BFnrgastro2012119_CR52","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"68","author":"RF Hwang","year":"2008","unstructured":"Hwang, R. F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918\u2013926 (2008).","journal-title":"Cancer Res."},{"key":"BFnrgastro2012119_CR53","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457\u20131461 (2009).","journal-title":"Science"},{"key":"BFnrgastro2012119_CR54","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/1940-6207.CAPR-10-0258","volume":"3","author":"PJ Grippo","year":"2010","unstructured":"Grippo, P. J. & Tuveson, D. A. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev. Res. (Phila.) 3, 1382\u20131387 (2010).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"BFnrgastro2012119_CR55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.2006.07.8824","volume":"25","author":"JR Infante","year":"2007","unstructured":"Infante, J. R. et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 25, 319\u2013325 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR56","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J. Clin. Oncol. 29, 4548\u20134554 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1158\/2159-8290.CD-11-0242","volume":"2","author":"KK Frese","year":"2012","unstructured":"Frese, K. K. et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2, 261\u2013269 (2012).","journal-title":"Cancer Discov."},{"key":"BFnrgastro2012119_CR58","first-page":"1547","volume":"145","author":"DS Klimstra","year":"1994","unstructured":"Klimstra, D. S. & Longnecker, D. S. K-ras mutations in pancreatic ductal proliferative lesions. Am. J. Pathol. 145, 1547\u20131550 (1994).","journal-title":"Am. J. Pathol."},{"key":"BFnrgastro2012119_CR59","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI59227","volume":"122","author":"MA Collins","year":"2012","unstructured":"Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639\u2013653 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrgastro2012119_CR60","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/gut.2009.186817","volume":"59","author":"CJ Grocock","year":"2010","unstructured":"Grocock, C. J. et al. The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut 59, 357\u2013363 (2010).","journal-title":"Gut"},{"key":"BFnrgastro2012119_CR61","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1053\/j.gastro.2005.03.006","volume":"128","author":"L Yan","year":"2005","unstructured":"Yan, L. et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128, 2124\u20132130 (2005).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012119_CR62","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","volume":"17","author":"EK Rowinsky","year":"1999","unstructured":"Rowinsky, E. K., Windle, J. J. & Von Hoff, D. D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631\u20133652 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR63","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/156800911796191079","volume":"11","author":"M Porzner","year":"2011","unstructured":"Porzner, M. & Seufferlein, T. Novel approaches to target pancreatic cancer. Curr. Cancer Drug Targets 11, 698\u2013713 (2011).","journal-title":"Curr. Cancer Drug Targets"},{"key":"BFnrgastro2012119_CR64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/CCO.0b013e32816f76f0","volume":"19","author":"J Bendell","year":"2007","unstructured":"Bendell, J. & Goldberg, R. M. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr. Opin. Oncol. 19, 390\u2013395 (2007).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrgastro2012119_CR65","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1002\/cncr.25393","volume":"116","author":"G da Cunha Santos","year":"2010","unstructured":"da Cunha Santos, G. et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116, 5599\u20135607 (2010).","journal-title":"Cancer"},{"key":"BFnrgastro2012119_CR66","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1158\/0008-5472.CAN-07-5200","volume":"68","author":"A Jimeno","year":"2008","unstructured":"Jimeno, A. et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 68, 2841\u20132849 (2008).","journal-title":"Cancer Res."},{"key":"BFnrgastro2012119_CR67","unstructured":"RTOG 0848 protocol information. Radiation Therapy Oncology Group [online] , (2012)."},{"key":"BFnrgastro2012119_CR68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2165\/11592470-000000000-00000","volume":"25","author":"MA Lowery","year":"2011","unstructured":"Lowery, M. A. & O'Reilly, E. M. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. BioDrugs 25, 207\u2013216 (2011).","journal-title":"BioDrugs"},{"key":"BFnrgastro2012119_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1586\/17474124.2.5.673","volume":"2","author":"G Middleton","year":"2008","unstructured":"Middleton, G., Ghaneh, P., Costello, E., Greenhalf, W. & Neoptolemos, J. P. New Treatment options for advanced pancreatic cancer. Expert Rev. Gastroenterol. Hepatol. 2, 673\u2013696 (2008).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012119_CR70","doi-asserted-by":"crossref","unstructured":"Kindler, H. L. et al. A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G.) in patients (pts) with metastatic pancreatic cancer (mPC) [abstract]. J. Clin. Oncol. a4035 (2010).","DOI":"10.1200\/jco.2010.28.15_suppl.4035"},{"key":"BFnrgastro2012119_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrc3184","volume":"12","author":"LV Nguyen","year":"2012","unstructured":"Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133\u2013143 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrgastro2012119_CR72","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2174\/138161212799859701","volume":"18","author":"JA McCubrey","year":"2012","unstructured":"McCubrey, J. A. et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr. Pharm. Des. 18, 1784\u20131795 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrgastro2012119_CR73","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1245\/s10434-007-9583-5","volume":"14","author":"AN Shah","year":"2007","unstructured":"Shah, A. N. et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 14, 3629\u20133637 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrgastro2012119_CR74","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1053\/j.gastro.2011.08.009","volume":"141","author":"C Li","year":"2011","unstructured":"Li, C. et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141, 2218\u20132227 e5 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012119_CR75","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc3035","volume":"11","author":"P Ranganathan","year":"2011","unstructured":"Ranganathan, P., Weaver, K. L. & Capobianco, A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 11, 338\u2013351 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrgastro2012119_CR76","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1517\/14728221003769895","volume":"14","author":"E Ristorcelli","year":"2010","unstructured":"Ristorcelli, E. & Lombardo, D. Targeting Notch signaling in pancreatic cancer. Expert Opin. Ther. Targets 14, 541\u2013552 (2010).","journal-title":"Expert Opin. Ther. Targets"},{"key":"BFnrgastro2012119_CR77","first-page":"1105","volume":"31","author":"Z Wang","year":"2011","unstructured":"Wang, Z. et al. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 31, 1105\u20131113 (2011).","journal-title":"Anticancer Res."},{"key":"BFnrgastro2012119_CR78","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1053\/j.gastro.2009.01.008","volume":"136","author":"R Plentz","year":"2009","unstructured":"Plentz, R. et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136, 1741\u20131749 (2009).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012119_CR79","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1084\/jem.20111923","volume":"209","author":"N Cook","year":"2012","unstructured":"Cook, N. et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med. 209, 437\u2013444 (2012).","journal-title":"J. Exp. Med."},{"key":"BFnrgastro2012119_CR80","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc2899","volume":"10","author":"JP Morris 4th","year":"2010","unstructured":"Morris, J. P. 4th, Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683\u2013695 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrgastro2012119_CR81","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/NEJMcibr0905857","volume":"361","author":"M Hidalgo","year":"2009","unstructured":"Hidalgo, M. & Maitra, A. The hedgehog pathway and pancreatic cancer. N. Engl. J. Med. 361, 2094\u20132096 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2012119_CR82","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1126\/science.1175940","volume":"324","author":"P Olson","year":"2009","unstructured":"Olson, P. & Hanahan, D. Cancer. Breaching the cancer fortress. Science 324, 1400\u20131401 (2009).","journal-title":"Science"},{"key":"BFnrgastro2012119_CR83","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/gut.2007.148189","volume":"57","author":"G Feldmann","year":"2008","unstructured":"Feldmann, G. et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57, 1420\u20131430 (2008).","journal-title":"Gut"},{"key":"BFnrgastro2012119_CR84","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1158\/1535-7163.MCT-08-0573","volume":"7","author":"G Feldmann","year":"2008","unstructured":"Feldmann, G. et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 7, 2725\u20132735 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrgastro2012119_CR85","doi-asserted-by":"crossref","unstructured":"Stephenson, J. et al. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer [abstract 4114]. J. Clin. Oncol. 29 (2011).","DOI":"10.1200\/jco.2011.29.15_suppl.4114"},{"key":"BFnrgastro2012119_CR86","unstructured":"Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Infinity Pharmaceuticals [online] , (2012)."},{"key":"BFnrgastro2012119_CR87","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612\u20131616 (2011).","journal-title":"Science"},{"key":"BFnrgastro2012119_CR88","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","volume":"95","author":"SA Hahn","year":"2003","unstructured":"Hahn, S. A. et al. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl Cancer Inst. 95, 214\u2013221 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrgastro2012119_CR89","doi-asserted-by":"publisher","unstructured":"Bartsch, D. K., Gress, T. M. & Langer, P. Familial pancreatic cancer\u2014current knowledge. Nat. Rev. Gastroenterol. Hepatol. http:\/\/dx.doi\/org\/10.1038\/nrgastro.2012.111 .","DOI":"10.1038\/nrgastro.2012.111"},{"key":"BFnrgastro2012119_CR90","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrc2812","volume":"10","author":"M Rouleau","year":"2010","unstructured":"Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293\u2013301 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrgastro2012119_CR91","first-page":"1417","volume":"31","author":"DR Fogelman","year":"2011","unstructured":"Fogelman, D. R. et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 31, 1417\u20131420 (2011).","journal-title":"Anticancer Res."},{"key":"BFnrgastro2012119_CR92","unstructured":"US National Library of Medicine. Study to assess the safety and tolerability of a PARP inhibitor in combination with gemcitabine in pancreastic cancer. ClinicalTrials.gov [online] , (2012)."},{"key":"BFnrgastro2012119_CR93","doi-asserted-by":"publisher","first-page":"11536","DOI":"10.1158\/0008-5472.CAN-05-2843","volume":"65","author":"H Sawai","year":"2005","unstructured":"Sawai, H. et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res. 65, 11536\u201311544 (2005).","journal-title":"Cancer Res."},{"key":"BFnrgastro2012119_CR94","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.surg.2005.07.007","volume":"138","author":"Y Ito","year":"2005","unstructured":"Ito, Y. et al. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 138, 788\u2013794 (2005).","journal-title":"Surgery"},{"key":"BFnrgastro2012119_CR95","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells, S. A. Jr et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134\u2013141 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2012119_CR96","unstructured":"US National Library of Medicine. Clinical trial comparing gemcitabine and vandetanib therapy with gemcitabine alone in pancreatic cancer. ClinicalTrial.gov [online] , (2012)."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.119","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:45:02Z","timestamp":1684467902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2012.119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,26]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BFnrgastro2012119"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2012.119","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,26]]}}}